Atomoxetine

Pharmacologic Category

Norepinephrine Reuptake Inhibitor, Selective

Dosing: Adult

Attention-deficit/hyperactivity disorder (ADHD) treatment: Oral: Note: Atomoxetine may be discontinued without tapering.

Initial: 40 mg/day, increase after minimum of 3 days to 80 mg/day; may administer as a single daily dose in the morning or as 2 evenly divided doses in the morning and late afternoon/early evening. May increase (if optimal response has not been achieved) to 100 mg/day after an additional 2 to 4 weeks. Maximum: 100 mg/day.

Dosage adjustment in patients receiving strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) or patients known to be CYP2D6 poor metabolizers: Initial: 40 mg/day; if tolerating therapy but inadequate response, may increase after minimum of 4 weeks to 80 mg/day.

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Use has not been evaluated in the elderly.

Dosing: Renal Impairment: Adult

No dosage adjustment necessary.

Dosing: Hepatic Impairment: Adult

Mild impairment (Child-Pugh class A): No dosage adjustment provided in manufacturer's labeling.

Moderate impairment (Child-Pugh class B): Reduce dose to 50% of normal dose.

Severe impairment (Child-Pugh class C): Reduce dose to 25% of normal dose.

Dosing: Pediatric

Attention-deficit/hyperactivity disorder: Children ≥6 years and Adolescents:

Patient weight ≤70 kg: Oral: Initial: ~0.5 mg/kg/day; increase after a minimum of 3 days to ~1.2 mg/kg/day; may administer either once daily in the morning or in 2 evenly divided doses and administered in the morning and late afternoon/early evening; maximum daily dose: 1.4 mg/kg/day or 100 mg/day, whichever is less. Note: Doses >1.2 mg/kg/day have not been shown to provide additional benefit.

Dosage adjustment with concurrent strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) use or patients known to be CYP2D6 poor metabolizers: Oral: Initial: 0.5 mg/kg/day; if tolerating therapy but inadequate response, may increase after a minimum of 4 weeks to 1.2 mg/kg/day.

Patient weight >70 kg: Oral: Initial: 40 mg once daily; increase after a minimum of 3 days to ~80 mg daily; may administer either once daily in the morning or in 2 evenly divided doses and administered in morning and late afternoon/early evening. If optimal response has not been achieved after an additional 2 to 4 weeks of therapy, may increase dose up to a maximum daily dose: 100 mg/day.

Dosage adjustment with concurrent strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) use or patients known to be CYP2D6 poor metabolizers: Oral: Initial: 40 mg once daily; if tolerating therapy but inadequate response, may increase after a minimum of 4 weeks to 80 mg/day.

Dosing: Renal Impairment: Pediatric

Children ≥6 years and Adolescents: No dosage adjustments are recommended.

Dosing: Hepatic Impairment: Pediatric

Children ≥6 years and Adolescents:

Moderate hepatic impairment (Child-Pugh class B): Administer 50% of normal dose

Severe hepatic impairment (Child-Pugh class C): Administer 25% of normal dose

Use: Labeled Indications

Attention-deficit/hyperactivity disorder: Treatment of attention-deficit/hyperactivity disorder (ADHD)

* See Uses in AHFS Essentials for additional information.

Comparative Efficacy

• ATOMOXETINE

Clinical Practice Guidelines

Attention-Deficit/Hyperactivity Disorder:

CPIC, “Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy,” 2019

National Institute for Health and Clinical Excellence, "Attention Deficit Hyperactivity Disorder: Diagnosis and Management," March 2018

Administration: Oral

Administer without regard to food. Do not crush, chew, or open capsule; swallow whole. Note: Atomoxetine is an ocular irritant; if capsule is opened inadvertently and contents come into contact with eye, flush eye immediately with water and obtain medical advice; wash hands and any potentially contaminated surface as soon as possible.

Administration: Pediatric

Oral: May be administered without regard to food. Do not crush, chew, or open capsule; swallow whole with water or other liquids. Note: Atomoxetine is an ocular irritant; if capsule is opened inadvertently and contents come into contact with eye, flush eye immediately with water and obtain medical advice; wash hands and any potentially contaminated surface as soon as possible.

Storage/Stability

Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat attention deficit problems with hyperactivity.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Abdominal pain

• Trouble sleeping

• Nausea

• Vomiting

• Lack of appetite

• Dry mouth

• Constipation

• Loss of strength and energy

• Fatigue

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Depression like suicidal ideation, anxiety, emotional instability, agitation, irritability, panic attacks, mood changes, behavioral changes, or confusion

• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin

• Severe cerebrovascular disease like change in strength on one side is greater than the other, trouble speaking or thinking, change in balance, or vision changes

• Vision changes

• Sensing things that seem real but are not

• Fast heartbeat

• Abnormal heartbeat

• Slow heartbeat

• Severe headache

• Trouble urinating

• Sexual dysfunction

• Erection that lasts more than 4 hours

• Chest pain

• Shortness of breath

• Severe dizziness

• Passing out

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021411s048lbl.pdf#page=19, must be dispensed with this medication.

Contraindications

Hypersensitivity to atomoxetine or any component of the formulation; use with or within 14 days of MAO inhibitors; narrow-angle glaucoma; current or history of pheochromocytoma; severe cardiac or vascular disorders in which the condition would be expected to deteriorate with clinically important increases in blood pressure (eg, 15 to 20 mm Hg) or heart rate (eg, 20 beats/minute).

Canadian labeling: Additional contraindications (not in US labeling): Symptomatic cardiovascular diseases, moderate to severe hypertension; advanced arteriosclerosis; uncontrolled hyperthyroidism

Warnings/Precautions

Concerns related to adverse effects:

• Aggressive behavior: New or worsening symptoms of hostility or aggressive behaviors have been associated with atomoxetine, particularly with the initiation of therapy.

• Allergic reactions: Anaphylactic reactions, angioneurotic edema, urticaria, and rash may occur (rare).

• Altered cardiac conduction: In clinical trials at therapeutic doses, atomoxetine consistently did not prolong the QT/QTc interval; however, one placebo-controlled study in healthy CYP2D6 poor metabolizers demonstrated a statistically significant increase in QTc with increasing atomoxetine concentrations (Loghin 2013; Martinez-Raga 2013). Case reports suggest that atomoxetine overdose may increase the QT interval; however, this occurred when atomoxetine was combined with other agents known to have QT prolongation potential or inhibit CYP2D6 (Barker 2004; Sawant 2004). Atomoxetine, at high concentrations ex vivo, has demonstrated hERG channel block (Scherer 2009).

• Cardiovascular events: Atomoxetine has been associated with serious cardiovascular events including sudden death in children and adolescents and sudden death, stroke, and MI in adult patients with preexisting structural cardiac abnormalities or other serious heart problems. Atomoxetine should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Prior to initiating atomoxetine, assess medical history and family history of sudden death or ventricular arrhythmia; conduct a physical exam to assess for cardiac disease; patients should receive further evaluation if findings suggest cardiac disease, such as ECG and echocardiogram. Promptly conduct cardiac evaluation in patients who develop exertional chest pain, unexplained syncope, or any other symptoms of cardiac disease during atomoxetine treatment.

• Hepatotoxicity: Use may be associated with rare but severe liver injury, including hepatic failure; monitor liver enzymes upon any sign or symptom of liver dysfunction (eg, pruritus, dark urine, jaundice, right upper quadrant tenderness, unexplained flu-like symptoms); discontinue and do not restart in patients with jaundice or laboratory evidence of liver injury. The majority of reported cases occurred within 120 days of initiation of therapy.

• Priapism: Prolonged (>4 hours), painful, and nonpainful penile erections have been reported (rarely) in pediatric and adult patients. There are 3 published reports in boys ages 11 to 12 years (Armstrong 2015; Goetz 2014; Wadoo 2009), only one of whom was solely taking atomoxetine; another of the 3 was attributed to risperidone. Despite at least 22 cases involving methylphenidate (Baytunca 2016; Bozkurt 2017; Chauhan 2016; Eiland 2014; Esnafoglu 2017; Mann 2017; Unver 2017), a 2013 FDA warning states priapism appears to be more common in patients taking atomoxetine than in patients taking methylphenidate. In reports involving methylphenidate, amphetamines, or atomoxetine, priapism has been reported with different formulations, doses, following dose changes, and during periods of withdrawal. Patients with certain hematological dyscrasias (eg, sickle cell disease), malignancies, perineal trauma, or concomitant use of alcohol, illicit drugs, or other medications associated with priapism may be at increased risk (Eiland 2014). Patients who develop abnormally sustained or frequent and painful erections should discontinue therapy and seek immediate medical attention. In patients with severe cases of priapism that were slow to resolve and/or required detumescence by aspiration, avoidance of stimulants and atomoxetine may be preferred (Eiland 2014).

• Psychiatric effects: Treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania) may occur in children and adolescents without a prior history of psychotic illness or mania. Consider discontinuation of treatment if symptoms occur.

Disease-related concerns:

• ADHD and comorbidities: Randomized, controlled trials have demonstrated that atomoxetine does not worsen anxiety in patients with existing anxiety disorders or tics related to Tourette disorder.

• Bipolar disorder: Use caution in patients with comorbid bipolar disorder; therapy may induce mixed/manic episodes. Atomoxetine is not approved for major depressive disorder; patients presenting with depressive symptoms should be screened for bipolar disorder.

• Cardiovascular disorders: Atomoxetine may increase BP and heart rate (HR); most pediatric patients may experience a moderate increase in BP and/or HR; a large, pooled analysis reported more pronounced increases in BP (≥15 to 20 mm Hg) and HR (≥20 bpm) in 8% to 12% of pediatric patients (Reed 2016). CYP2D6 poor metabolizers may experience greater increases in BP and HR. Use with caution in patients with underlying conditions (eg, hypertension, tachycardia, cardiovascular or cerebrovascular disease) that could be worsened by BP or HR increases and in patients predisposed to hypotension or with conditions associated with abrupt HR or BP changes. Avoid use in patients with severe cardiac or vascular disorders that would be expected to deteriorate with clinically significant increases in BP.

• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustments necessary in moderate and severe hepatic insufficiency.

• Urinary retention: Use with caution in patients with a history of urinary retention or bladder outlet obstruction; may cause urinary retention/hesitancy.

Special populations:

• CYP2D6 poor metabolizers: Dosage adjustments are recommended in CYP2D6 poor metabolizers; these patients have increased exposure to atomoxetine.

• Pediatric: [US Boxed Warning]: Use with caution in pediatric patients; may be an increased risk of suicidal ideation. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior; especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The family or caregiver should be instructed to closely observe the patient and communicate condition with health care provider. Growth should be monitored during treatment. Height and weight gain may be reduced during the first 9 to 12 months of treatment, but should recover by 3 years of therapy.

Other warnings/precautions:

• ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.

* See Cautions in AHFS Essentials for additional information.

Warnings: Additional Pediatric Considerations

CNS stimulant treatment has been associated with sudden death in children and adolescents with preexisting structural cardiac abnormalities; a retrospective case-control study reported an association with stimulants and sudden unexplained death in youth (Gould 2009); however, as noted in reviews (Martinez-Raga 2013; Westover 2012) several large studies have not found an association between prescription stimulants and cardiovascular events; though most retrospective studies were large (n=55,383 to 2,131,953), some had statistical power or methodological limitations (Westover 2012). A large retrospective cohort study involving 1,200,438 children and young adults (aged 2 to 24 years) prescribed ADHD medication (methylphenidate, dexmethylphenidate, dextroamphetamines, amphetamine salts, pemoline, or atomoxetine) found no evidence that ADHD medication was associated with an increased risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31 to 1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57 to 1.89) users compared with nonusers, nor in current compared with former users. Results were similar with multiple alternative analyses to assess for bias or study assumptions. While point estimates of relative risks for ADHD drugs did not demonstrate increased risk, the upper limit of the 95% CI suggested a doubling of the risk could not be ruled out, although absolute magnitude of increased risk would be low. Data on any individual medication, other than methylphenidate, were too sparse for separate regression analyses (Cooper 2011). Prior to treatment with medications for ADHD, the American Heart Association and the American Academy of Pediatrics recommend that all children and adolescents diagnosed with ADHD have a thorough cardiovascular assessment, including patient and family health histories, determination of all medications used (prescribed and over-the-counter), and a physical examination focused on cardiovascular disease risk factors. An ECG is not mandatory but is reasonable to consider prior to stimulant medication therapy. Prompt evaluation and appropriate referral and testing, if warranted, should occur if any cardiac symptoms present (Vetter 2008).

In pediatric patients, growth (height and weight) has been observed to lag behind growth predicted by normative population data during the initial 9 to 12 months of therapy but subsequently rebound and recover to normative values by 3 years of therapy; this growth pattern has been observed to be independent of pubertal status at the time of initiation and was similar between CYP2D6 poor and extensive metabolizers; growth parameters should be monitored during treatment. Reductions in weight may be secondary to decreased appetite resulting from GI side effects (eg, nausea, vomiting, abdominal pain); the incidence of GI effects is generally highest in the first several months of treatment (Reed 2016). Evaluation of the effect of stimulants on growth in ADHD diagnosed children <12 years receiving treatment for at least 3 years with stimulants has shown decreased height and weight changes over time compared to age matched control; height: 4.7 to 5.5 cm/year compared to 6.3 cm/year and 2.1 to 3.3 kg/year compared to 4.4 kg/year (Poulton 2016). In pediatric patients 8 to 17 years actively treated with stimulants, significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed compared to matched unmedicated cohorts; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched cohorts (38.3% to 21.6%) (Howard 2017). A longitudinal cohort-controlled trial reported no different in peak height velocity and final adult height in subjects with ADHD and/or treated with stimulants (Harstad 2014).

Reproductive Considerations

Appropriate contraception is recommended for sexually active women of childbearing potential (Heiligenstein 2003). An agent other than atomoxetine is preferred for the treatment of attention-deficit/hyperactivity disorder (ADHD) in women planning a pregnancy (Larsen 2015).

Pregnancy Considerations

In comparison to other agents used for the treatment of attention-deficit/hyperactivity disorder (ADHD), information related to atomoxetine use in pregnancy is limited (Bro 2015; Haervig 2014; Heiligenstein 2003; Ornoy 2018).

If medication is needed for the treatment of ADHD during pregnancy, an agent other than atomoxetine is preferred. Consider discontinuing or changing treatment in women who become pregnant during atomoxetine therapy (Larsen 2015).

Data collection to monitor pregnancy and infant outcomes following exposure to atomoxetine is ongoing. Health care providers are encouraged to enroll females exposed to atomoxetine during pregnancy in the National Pregnancy Registry for ADHD medications at 1-866-961-2388.

Breast-Feeding Considerations

It is not known if atomoxetine is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. An agent other than atomoxetine is preferred for the treatment of attention-deficit/hyperactivity disorder (ADHD) in women who are breastfeeding (Larsen 2015).

Briggs' Drugs in Pregnancy & Lactation

• Atomoxetine

Adverse Reactions

Percentages as reported in children and adults; some adverse reactions may be increased in "poor metabolizers" (CYP2D6). Frequency not always defined.

>10%:

Central nervous system: Headache (19%; children and adolescents), insomnia (1% to 19%), drowsiness (8% to 11%)

Dermatologic: Hyperhidrosis (4% to 15%)

Gastrointestinal: Xerostomia (17% to 35%), nausea (7% to 26%), decreased appetite (15% to 23%), abdominal pain (7% to 18%), vomiting (4% to 11%), constipation (1% to 11%)

Genitourinary: Erectile dysfunction (8% to 21%)

1% to 10%:

Cardiovascular: Increased diastolic blood pressure (5% to 9%; ≥15 mm Hg), systolic hypertension (4% to 5%), palpitations (3%), cold extremities (1% to 3%), syncope (≤3%), flushing (≥2%), orthostatic hypotension (≤2%), tachycardia (≤2%), prolonged QT interval on ECG

Central nervous system: Fatigue (6% to 10%), dizziness (5% to 8%), depression (4% to 7%), disturbed sleep (3% to 7%), irritability (5% to 6%), jitteriness (2% to 5%), abnormal dreams (4%), chills (3%), paresthesia (adults 3%; postmarketing observation in children), anxiety (≥2%), hostility (children and adolescents 2%), emotional lability (1% to 2%), agitation, restlessness, sensation of cold

Dermatologic: Excoriation (2% to 4%), skin rash (2%), pruritus, urticaria

Endocrine & metabolic: Weight loss (2% to 7%), decreased libido (3%), hot flash (3%), increased thirst (2%), menstrual disease

Gastrointestinal: Dyspepsia (4%), anorexia (3%), dysgeusia, flatulence

Genitourinary: Ejaculatory disorder (2% to 6%), urinary retention (1% to 6%), dysmenorrhea (3%), dysuria (2%), orgasm abnormal, pollakiuria, prostatitis, testicular pain, urinary frequency

Neuromuscular & skeletal: Tremor (1% to 5%), muscle spasm, weakness

Ophthalmic: Blurred vision (1% to 4%), conjunctivitis (1% to 3%), mydriasis

Respiratory: Pharyngolaryngeal pain

Miscellaneous: Therapeutic response unexpected (2%)

<1%, postmarketing, and/or case reports: Aggressive behavior, akathisia, alopecia, anaphylaxis, angioedema, cerebrovascular accident, change in libido, delusions, growth suppression (children), hallucination, hepatotoxicity, hypersensitivity reaction, hypoesthesia, hypomania, impulsivity, jaundice, lethargy, mania, myocardial infarction, panic attack, pelvic pain, priapism, Raynaud's phenomenon, rhabdomyolysis, seizure (including patients with no prior history or known risk factors for seizure), severe hepatic disease, suicidal ideation, tics

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• AtoMOXetine Allergy

Metabolism/Transport Effects

Substrate of CYP2C19 (minor), CYP2D6 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible. When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity. Risk D: Consider therapy modification

Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Asunaprevir is contraindicated in combination with drugs metabolized by CYP2D6 for which increased levels are associated with ventricular arrhythmias and sudden death (eg, thioridazine, flecanide, propafenone); use caution with any CYP2D6 substrate. Risk D: Consider therapy modification

Beta2-Agonists: AtoMOXetine may enhance the tachycardic effect of Beta2-Agonists. Risk C: Monitor therapy

CloBAZam: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CYP2D6 Inhibitors (Strong): May increase the serum concentration of AtoMOXetine. Management: Initiate atomoxetine at a reduced dose (patients who weigh up to 70 kg: 0.5 mg/kg/day; adults or patients who weigh 70 kg or more: 40 mg/day) in patients receiving a strong CYP2D6 inhibitor. Increase to usual target dose after 4 weeks if needed. Risk D: Consider therapy modification

Dacomitinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of dacomitinib with CYP2D6 subtrates that have a narrow therapeutic index. Risk D: Consider therapy modification

Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Iobenguane Radiopharmaceutical Products: Selective Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Risk X: Avoid combination

Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: May enhance the neurotoxic (central) effect of AtoMOXetine. Risk X: Avoid combination

Ozanimod: May enhance the hypertensive effect of Selective Norepinephrine Reuptake Inhibitors. Management: Concomitant use of ozanimod with selective norepinephrine reuptake inhibitors is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Risk D: Consider therapy modification

Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Sympathomimetics: AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Gene Testing Recommended

• CYP2D6 - Atomoxetine

Monitoring Parameters

Liver enzymes (upon signs/symptoms of liver dysfunction and for several weeks after discontinuation for liver dysfunction). Cardiac evaluation should be completed at baseline and on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment. Monitor blood pressure and heart rate (baseline, following dose increases and periodically during treatment); growth (weight and height) and appetite in children; weight in adults; sleep and behavioral changes.

Reference Range

Timing of serum samples: In normal, intermediate, and ultrarapid CYP26 metabolizers or in patients with unknown CYP2D6 metabolizer status, draw peak plasma concentrations 1 to 2 hours after dose. In intermediate CYP2D6 metabolizers, consider drawing peak plasma concentrations 2 to 4 hours after dose in patients with lower enzyme activity or if the *10 allele is present. For poor CYP2D6 metabolizers, draw peak plasma concentrations 4 hours after dose (Brown 2019; Hiemke 2018).

Therapeutic reference range: 200 to 1,000 ng/mL (782 to 3,910 nmol/L) (Hiemke 2018). Note: There is no clear correlation with therapeutic levels and efficacy or tolerability; base dosing on therapeutic response as opposed to serum concentrations (Hazell 2009; Michelson 2007). However, therapeutic drug levels may be useful in patients with CYP2D6 polymorphisms that have a poor treatment response (Brown 2019).

Laboratory alert level: 2,000 ng/mL (7,820 nmol/L) (Hiemke 2018).

Advanced Practitioners Physical Assessment/Monitoring

Use caution in presence of hepatic impairment, hypertension, and cardiovascular disease. Pediatric patients should be screened/monitored for cardiovascular conditions prior to and during use. Observe closely during first few months of therapy and when dose is changed. Monitor growth regularly.

Nursing Physical Assessment/Monitoring

Pediatric patients should be screened/monitored for cardiovascular conditions prior to treatment. Monitor growth (height and weight) regularly and for risk of suicide ideation.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Strattera: 10 mg, 18 mg

Strattera: 25 mg [contains fd&c blue #2 (indigotine)]

Strattera: 40 mg, 60 mg, 80 mg [contains corn starch, fd&c blue #2 (indigotine)]

Strattera: 100 mg [contains fd&c blue #2 (indigotine)]

Generic: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Strattera: 10 mg, 18 mg

Strattera: 25 mg, 40 mg, 60 mg, 80 mg, 100 mg [contains fd&c blue #2 (indigotine)]

Generic: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg

Anatomic Therapeutic Chemical (ATC) Classification

• N06BA09

Generic Available (US)

Yes

Pricing: US

Capsules (Atomoxetine HCl Oral)

10 mg (per each): $14.22 - $14.23

18 mg (per each): $14.22 - $14.23

25 mg (per each): $14.22 - $14.23

40 mg (per each): $7.60 - $15.47

60 mg (per each): $15.45 - $15.47

80 mg (per each): $16.67 - $16.69

100 mg (per each): $16.67 - $16.69

Capsules (Strattera Oral)

10 mg (per each): $15.82

18 mg (per each): $15.82

25 mg (per each): $15.82

40 mg (per each): $17.18

60 mg (per each): $17.18

80 mg (per each): $18.54

100 mg (per each): $18.54

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Selectively inhibits the reuptake of norepinephrine (Ki 4.5 nM) with little to no activity at the other neuronal reuptake pumps or receptor sites.

Pharmacodynamics/Kinetics

Note: The pharmacokinetics in pediatric patients ≥6 years of age have been shown to be similar to those of adult patients.

Duration of action: Up to 24 hours (Jain 2017)

Absorption: Rapid

Distribution: Vd: IV: 0.85 L/kg

Protein binding: 98%, primarily albumin

Metabolism: Hepatic, via CYP2D6 and CYP2C19; forms metabolites (4-hydroxyatomoxetine, active, equipotent to atomoxetine; N-desmethylatomoxetine, limited activity); Note: CYP2D6 poor metabolizers have atomoxetine AUCs that are ~10-fold higher and peak concentrations that are ~fivefold greater than extensive metabolizers; 4-hyroxyatomoxetine plasma concentrations are very low (extensive metabolizers: 1% of atomoxetine concentrations; poor metabolizers: 0.1% of atomoxetine concentrations

Bioavailability: 63% in extensive metabolizers; 94% in poor metabolizers

Half-life elimination: Atomoxetine: 5 hours (up to 24 hours in poor metabolizers); Active metabolites: 4-hydroxyatomoxetine: 6-8 hours; N-desmethylatomoxetine: 6-8 hours (34-40 hours in poor metabolizers)

Time to peak, plasma: 1-2 hours; delayed 3 hours by high-fat meal

Excretion: Urine (80%, as conjugated 4-hydroxy metabolite; <3% is excreted unchanged); feces (17%)

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: Extensive metabolizers with ESRD had higher systemic exposure (approximately a 65% increase), but there was no difference when exposure was corrected for mg/kg dose.

Hepatic function impairment: AUC is increased in extensive metabolizers with moderate or severe hepatic impairment.

Local Anesthetic/Vasoconstrictor Precautions

Use vasoconstrictor with caution. Atomoxetine may increase heart rate or blood pressure in the presence of pressor agents. Pressor agents include the vasoconstrictors epinephrine or mepivacaine and levonordefrin (Carbocaine® 2% with Neo-Cobefrin®)

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Xerostomia (normal salivary flow resumes upon discontinuation)

Effects on Bleeding

No information available to require special precautions

Related Information

• Drugs With Actionable Pharmacogenomic Recommendations
• Oral Medications That Should Not Be Crushed or Altered

Index Terms

Atomoxetine Hydrochloride; LY139603; Methylphenoxy-Benzene Propanamine; Tomoxetine

FDA Approval Date

November 26, 2002

References

American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr. 2008;29(4):335.[PubMed 18698199]

Armstrong WR, Grimsby GM, Jacobs MA. Pediatric priapism secondary to psychotherapeutic medications. Urology. 2015;86(2):376-378.[PubMed 26199163]

Barker MJ, Benitez JG, Ternullo S, et al. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol. 2004;46:130–132.[PubMed 15171487]

Baytunca MB, Kose S, Ozbaran B, Erermis S. Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent. Pediatr Int. 2016;58(1):61-63.[PubMed 26542690]

Biderman J, Heiligenstein JH, Faries DE, at al. Efficacy of Atomoxetine Versus Placebo in School-Age Girls With Attention-Deficit/Hyperactivity Disorder. Pediatrics. 2002;110(6). http://www.pediatrics.org/cgi/content/full/110/6/e75.

Bozkurt H, Şahin S. Olanzapine-induced priapism in a child with Asperger's Syndrome. Balkan Med J. 2017;34(1):85-87.[PubMed 28251031]

Bro SP, Kjaersgaard MI, Parner ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139-147. doi: 10.2147/CLEP.S72906[PubMed 25657597]

Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019;106(1):94-102. doi: 10.1002/cpt.1409.[PubMed 30801677]

Chauhan N, Grover S, Patidar V. Methylphenidate-induced priapism in a prepubertal boy. Indian J Psychiatry. 2016;58(4):475-476. J Psychopharmacol. 2015;29(12):1221-1230.[PubMed 28197010]

Clemow DB, Bushe CJ. Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol. 2015;29(12):1221-1230.[PubMed 26349559]

Cooper WO, Habel LA, Sox CM, et al. ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults. N Engl J Med. 2011;365(20):1896-1904.[PubMed 22043968]

Dopheide JA, Pliszka SR. Attention-Deficit-Hyperactivity Disorder: An Update. Pharmacotherapy. 2009;29(6):656-679.[PubMed 19476419]

Eiland LS, Bell EA, Erramouspe J. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. Ann Pharmacother. 2014;48(10):1350-1355. doi: 10.1177/1060028014541791.[PubMed 24982313]

Esnafoglu E, Demir EY. Hallucination and priapism associated with methylphenidate usage: Two case reports. Indian J Psychiatry. 2017;59(3):386-387.[PubMed 29085103]

Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents [published correction appears in N Engl J Med. 2015;372(2):197]. N Engl J Med. 2014;370(9):838-846.[PubMed 24571756]

Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns of rare risk of long-lasting erections in males taking methylphenidate ADHD medications and has approved label changes. https://www.fda.gov/drugs/drugsafety/ucm375796.htm. Published December 17, 2013. Accessed September 27, 2018.

Goetz M, Surman CB. Prolonged penile erections associated with the use of atomoxetine and aripiprazole in an 11-year-old boy. J Clin Psychopharmacol. 2014;34(2):275-276.[PubMed 24577257]

Gould MS, Walsh BT, Munfakh JL, et al. Sudden Death and Use of Stimulant Medications in Youths. Am J Psychiatry. 2009;166(9):992-1001.[PubMed 19528194]

Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23(5):526-533. doi:10.1002/pds.3600[PubMed 24590619]

Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics. 2014;134(4):e935-944.[PubMed 25180281 ]

Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord. 2009;1(2):201-210. doi: 10.1007/s12402-009-0012-4.[PubMed 20234828]

Heiligenstein J, Michelson D, Wernicke J, et al. Atomoxetine and Pregnancy; Author Reply. J Am Acad Child Adolesc Psychiatry. 2003;42(8):884-885.

Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62. doi: 10.1055/s-0043-116492.[PubMed 28910830]

Howard JT, Walick KS, Rivera JC. Preliminary Evidence of an Association Between ADHD Medications and Diminished Bone Health in Children and Adolescents. J Pediatr Orthop. 2017;37(5):348-354.[PubMed 26398435 ]

Jain R, Jain S, Montano B. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord. 2017;19(5). doi: 10.4088/PCC.17nr02153.[PubMed 28906602]

Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784.[PubMed 12108801]

Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. doi:10.1111/acps.12479[PubMed 26344706]

Loghin C, Haber H, Beasley CM, et al. Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. Br J Clin Pharmacol. 2013;75(2):538-549.[PubMed 22803597]

Mann RA, George AK. Recurrent priapism in a military veteran receiving treatment for PTSD. Mil Med. 2017;182(11):e2104-e2107.[PubMed 29087891]

Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 2013;27(1):15-30.[PubMed 23160939]

Michelson D, Allen AJ, Busner J, et al. Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study. Am J Psychiatry. 2002;159(11):1896-1901.[PubMed 12411225]

Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study. Pediatrics. 2001;108(5). http://www.pediatrics.org/cgi/content/full/108/5/e83.[PubMed 11694667 ]

Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46(2):242-251. doi: 10.1097/01.chi.0000246056.83791.b6.[PubMed 17242628]

Newcorn JH, Michelson D, Kratochvil CJ, et al. Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder. Pediatrics. 2006;118(6):e1701-e1706.[PubMed 17101710]

Ornoy A. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res. 2018;35(3):46. doi:10.1007/s11095-017-2323-z[PubMed 29411149]

Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451-453.[PubMed 18676566]

Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894:921.[PubMed 17581453]

Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. Int Clin Psychopharmacol. 2016;31(2):93-99.[PubMed 26544899 ]

Reed VA, Buitelaar JK, Anand E, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs. 2016;30(7):603-628.[PubMed 27290715]

Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [letter]. Am J Psychiatry. 2004;161:757.[PubMed 15056530]

Scherer D, Hassel D, Bloehs R, et al. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol. 2009;156:226–236.[PubMed 19154426]

Spencer T, Heiligenstein JH, Biederman J, et al. Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry. 2002;63(12):1140-1147.[PubMed 12523874]

Strattera (atomoxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; February 2020.

Strattera (atomoxetine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; October 2015.

Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management; Wolraich M, Brown L, Brown RT, et al. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2011;128(5):1007-1022.[PubMed 22003063]

Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, et al. Supplemental information: Implementing the key action statements: An algorithm and explanation for process of care for the evaluation, diagnosis, treatment, and monitoring of ADHD in children and adolescents. Pediatrics. 2011. http://pediatrics.aappublications.org/content/pediatrics/suppl/2011/10/11/peds.2011-2654.DC1/zpe611117822p.pdf.

Unver H, Memik NC, Simsek E. Priapism associated with the addition of risperidone to methylphenidate monotherapy: a case report. North Clin Istanb. 2017;4(1):85-88.[PubMed 28752150]

Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423.[PubMed 18427125]

Wadoo O, Chalhoub N. Risperidone-induced sexual dysfunction in a prepubertal child - a case report. J Psychopharmacol. 2009;23(6):727-728.[PubMed 18562402]

Wernicke JF, Kratochvil CJ. Safety Profile of Atomoxetine in the Treatment of Children and Adolescents With ADHD. J Clin Psychiatry. 2002;63(suppl 12):50-55.[PubMed 12562062 ]

Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC Cardiovasc Disord. 2012;12:41.[PubMed 22682429]

Yamaguchi H, Nagumo K, Nakashima T, Kinugawa Y, Kumaki S. Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine. Eur J Pediatr. 2014;173(12):1631-1634.[PubMed 24233333]

Brand Names: International

Abretia (CL, PE, UY); Artlex (KR); Atomafutix (EG); Atomerra (AU); Atomic (IL); Atomoxapex (EG); Attentho (CO); Attentin (BD); Attentrol (IN); Axepta (IN); Deaten (CL); Exotrima (CR, DO, GT, HN, NI, PA, SV); Focusfar (CR, DO, GT, HN, NI, PA, SV); MIXRE (TW); Omanoz (EG); Passiva (PE); Recit (AR); Sophos (PY); Stratomox (EG); Strattera (AE, AR, AT, AU, BB, BE, BG, BH, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, ZA); Suev (BD); Xenocy (ID)

Last Updated 5/2/20